180 related articles for article (PubMed ID: 32641911)
1. Use of Simulation Strategies to Predict Subtherapeutic Meropenem Exposure Caused by Augmented Renal Clearance in Critically Ill Pediatric Patients With Sepsis.
Avedissian SN; Skochko SM; Le J; Hingtgen S; Harvey H; Capparelli EV; Richardson A; Momper J; Mak RH; Neely M; Bradley JS
J Pediatr Pharmacol Ther; 2020; 25(5):413-422. PubMed ID: 32641911
[TBL] [Abstract][Full Text] [Related]
2. Optimal Dosing of Meropenem in a Small Cohort of Critically Ill Children Receiving Continuous Renal Replacement Therapy.
Tan WW; Watt KM; Boakye-Agyeman F; Cohen-Wolkowiez M; Mok YH; Yung CF; Chan YH
J Clin Pharmacol; 2021 Jun; 61(6):744-754. PubMed ID: 33314163
[TBL] [Abstract][Full Text] [Related]
3. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Meropenem in Critically Ill Young Children.
Cies JJ; Moore WS; Enache A; Chopra A
J Pediatr Pharmacol Ther; 2017; 22(4):276-285. PubMed ID: 28943823
[TBL] [Abstract][Full Text] [Related]
5. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
[TBL] [Abstract][Full Text] [Related]
6. Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study.
Kumta N; Heffernan AJ; Cotta MO; Wallis SC; Livermore A; Starr T; Wong WT; Joynt GM; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0014222. PubMed ID: 35862757
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study.
Braune S; König C; Roberts JA; Nierhaus A; Steinmetz O; Baehr M; Kluge S; Langebrake C
Crit Care; 2018 Jan; 22(1):25. PubMed ID: 29382394
[TBL] [Abstract][Full Text] [Related]
8. Decreased meropenem levels in Intensive Care Unit patients with augmented renal clearance: benefit of therapeutic drug monitoring.
Tröger U; Drust A; Martens-Lobenhoffer J; Tanev I; Braun-Dullaeus RC; Bode-Böger SM
Int J Antimicrob Agents; 2012 Oct; 40(4):370-2. PubMed ID: 22795654
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetic Model and Dosing Simulation of Meropenem Using Measured Creatinine Clearance for Patients with Sepsis.
Fukumoto S; Ohbayashi M; Okada A; Kohyama N; Tamatsukuri T; Inoue H; Kato A; Kotani T; Sagara H; Dohi K; Kogo M
Ther Drug Monit; 2023 Jun; 45(3):392-399. PubMed ID: 36253888
[TBL] [Abstract][Full Text] [Related]
10. Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization.
Cojutti PG; Gatti M; Rinaldi M; Tonetti T; Laici C; Mega C; Siniscalchi A; Giannella M; Viale P; Pea F
Front Pharmacol; 2021; 12():781892. PubMed ID: 34955851
[No Abstract] [Full Text] [Related]
11. Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation.
Lee DH; Kim HS; Park S; Kim HI; Lee SH; Kim YK
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834278
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units.
Jaruratanasirikul S; Thengyai S; Wongpoowarak W; Wattanavijitkul T; Tangkitwanitjaroen K; Sukarnjanaset W; Jullangkoon M; Samaeng M
Antimicrob Agents Chemother; 2015; 59(6):2995-3001. PubMed ID: 25753628
[TBL] [Abstract][Full Text] [Related]
13. Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis.
Tsai D; Stewart P; Goud R; Gourley S; Hewagama S; Krishnaswamy S; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2016 Nov; 48(5):542-546. PubMed ID: 27771187
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of meropenem in children with sepsis undergoing extracorporeal life support: A prospective observational study.
Wang Y; Li Z; Chen W; Yan G; Wang G; Lu G; Chen C
J Clin Pharm Ther; 2021 Jun; 46(3):754-761. PubMed ID: 33476064
[TBL] [Abstract][Full Text] [Related]
15. Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients.
Zhao YC; Zou Y; Xiao YW; Wang F; Zhang BK; Xiang DX; Yu F; Luo H; Sandaradura I; Yan M
Infect Dis Ther; 2022 Feb; 11(1):201-216. PubMed ID: 34748194
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation.
Idoate Grijalba AI; Aldaz Pastor A; Marquet P; Woillard JB
Eur J Clin Pharmacol; 2019 Oct; 75(10):1405-1414. PubMed ID: 31338539
[TBL] [Abstract][Full Text] [Related]
17. Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function.
Gijsen M; Elkayal O; Annaert P; Van Daele R; Meersseman P; Debaveye Y; Wauters J; Dreesen E; Spriet I
Infect Drug Resist; 2022; 15():53-62. PubMed ID: 35035223
[TBL] [Abstract][Full Text] [Related]
18. Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.
Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264846
[TBL] [Abstract][Full Text] [Related]
19. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
[TBL] [Abstract][Full Text] [Related]
20. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
